Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment [PDF]
, 2022 Young Eun Chon +8 more
openalex +1 more source
Cancer Science, EarlyView.SPP1 was identified as a key driver of intratumoral fibrosis and hepatocellular carcinoma (HCC) progression through transcriptomic, histological, and functional analyses. Mechanistically, SPP1 promotes HSC activation and fibrosis via the SPP1–CD44–GLI1 axis, and pharmacologic inhibition of Hedgehog signaling effectively reduces tumor growth and ...
Atsushi Nara +16 more
wiley +1 more source
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer [PDF]
, 2021 Andrea Ardizzoni +13 more
openalex +1 more source
Cancer Science, EarlyView.The global Phase 3 IMpower010 study (NCT02486718) evaluated atezolizumab versus best supportive care (BSC) after complete resection and adjuvant platinum‐based chemotherapy in patients with stage IB–IIIA non‐small cell lung cancer (NSCLC). Here, we report updated efficacy and safety results from the disease‐free survival (DFS) final and overall ...
Morihito Okada +9 more
wiley +1 more source
Current OncologyThis epidemiological model forecasted reductions in recurrences and recurrence treatment cost savings with adjuvant atezolizumab vs best supportive care among Canadians with stage II-IIIA non-small cell lung cancer (NSCLC) at national and provincial ...
Quincy Chu +4 more
doaj +1 more source
Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. [PDF]
, 2019 Despite being one of the most common cancers, treatment options for prostate cancer are limited. Novel approaches for advanced disease are needed. We evaluated the relative rate of use of clinical-grade next generation sequencing (NGS) in prostate cancer,
Carter, Jennifer L +4 more
core
Cancer Science, EarlyView.We uncovered pronounced and heterogeneous tumor senescence in EOCRC, independent of age. By integrating multi‐omics and single‐cell analyses, we developed EO‐Senscore, a prognostic tool that stratifies patients by immune phenotype and therapy response, enabling precision treatment using immunotherapy or senolytic agents. ABSTRACT Early‐onset colorectal
Du Cai +11 more
wiley +1 more source
P5-2 The addition of atezolizumab to chemotherapy in non-small cell lung cancer: Trial-based review and meta analysis [PDF]
, 2023 Nadya Keumala Fitri +3 more
openalex +1 more source
Pembrolizumab for Early‐Stage Triple‐Negative Breast Cancer: KEYNOTE‐522 Japan Subgroup Analysis
Cancer Science, EarlyView.In the global, phase 3 KEYNOTE‐522 study of high‐risk early‐stage triple‐negative breast cancer (TNBC), neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab improved efficacy outcomes versus neoadjuvant chemotherapy alone. In this analysis of Japanese participants from KEYNOTE‐522, neoadjuvant pembrolizumab plus chemotherapy ...
Masato Takahashi +16 more
wiley +1 more source
Immunothérapie : une révolution dans la prise en charge du cancer de la vessie ? [Immunotherapy : a revolution in the management of urothelial bladder cancer ?] [PDF]
, 2017 The treatment of urothelial bladder cancer has changed very little in recent years, with high rates of disease recurrence and progression, even in low aggressive urothelial bladder cancer. Immunotherapy has already proven its effectiveness as a treatment
Adam, S.M. +3 more
core